The research information on using atropine for myopia control is evolving. Previous research indicated 0.01% atropine was best, but newer research says otherwise. In this clinical case, practitioners discuss treatment strategies, which are put in research context with clinical pearls for practice.
A child has an allergic reaction to low dose atropine – or does he? Here practitioners consider the possible causes, with advice for management. We then frame this discussion in view of the evidence-base with take home clinical messages.
Atropine can be used for myopia control as a monotherapy or as an adjunct to an optical intervention – we discuss patient selection, atropine combination treatments, how to taper and when to stop.
Read these three clinical complex atropine cases where general health conditions required careful consideration of atropine prescribing for myopia control.
Most atropine currently prescribed for myopia control is compounded. How could this influence consistency of treatment and research results? What could current research lead to in future prescribing? Read more here.
As there are systemic side effects of atropine eye drops, they could be contraindicated in young patients with some conditions, syndromes, and when taking specific systemic medications. Medication safety is also discussed.
Atropine has been the apparent hero of myopia management since the 2006 & more recently, low dose (0.01%) atropine has become the new hero. This article describes how lower concentrations work to balance efficacy and side effects, and which should we select now.
In 2010 Visique Rose Optometrists in New Zealand launched its myopia control clinic. The aim of this clinic was to
